HC Wainwright & Co. Maintains Buy on Inozyme Pharma, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White maintains a 'Buy' rating on Inozyme Pharma (NASDAQ:INZY) but lowers the price target from $19 to $16.

August 04, 2023 | 4:52 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Inozyme Pharma's price target has been lowered from $19 to $16 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintenance of the 'Buy' rating indicates that the analyst still sees potential upside, which could counterbalance the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100